-

IT Investor Alert: Gartner, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Minimized Slowdown Risks: Levi & Korsinsky

Time-Sensitive: Allegations Focus on Macroeconomic and Tariff Risk Representations

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Gartner, Inc. (NYSE: IT) of a pending securities class action. Class Period: February 4, 2025 through February 2, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

Gartner shares fell from a Class Period high of $336.71 to $160.16, representing losses of over $176 per share. The Court has set May 18, 2026 as the deadline to apply for lead plaintiff appointment.

How Seasonality and Tariff Risks Were Allegedly Downplayed

The lawsuit asserts that throughout the Class Period, Gartner's management created a false impression that they possessed reliable information about the Company's projected consulting revenue outlook and anticipated Contract Value growth while minimizing the risk of further, more severe slowdowns driven by seasonality, macroeconomic fluctuations, and tariff impacts.

As alleged, when management acknowledged that "decision cycles have extended" due to tariff impacts during the May 2025 earnings call, they simultaneously characterized the pipeline as "very robust" and framed cost-cutting as merely "a slight belt tightening." The action claims this characterization concealed the severity of the deceleration already underway across non-federal business lines.

Tariff and DOGE Policy Headwinds in Gartner's Markets

  • The lawsuit contends that management knew purchase decisions were being escalated from functional leaders to CFOs and CEOs at a "record pace," yet publicly projected confidence in near-term CV stability
  • As alleged, 78% of CEOs surveyed by Gartner itself indicated they were implementing cost-cutting measures, a data point management possessed internally before investors understood its impact on renewals
  • The action claims that tariff-driven spending freezes affected not only directly impacted companies but spread to industries with no direct tariff exposure, broadening the headwind beyond what was disclosed
  • Consulting segment guidance remained unchanged at $575 million through two consecutive quarters despite alleged internal knowledge that backlog and pipeline assumptions had deteriorated
  • The complaint asserts that Canadian and Australian markets, representing approximately 6% of global CV, experienced outright year-over-year declines that management failed to adequately flag as systemic risks

Speak with an attorney about recovering damages or call (212) 363-7500.

"Investors deserve transparency about material risks that could affect their investments. When a company's own survey data reveals recessionary-level CEO confidence and widespread cost-cutting among its client base, shareholders are entitled to understand how those conditions affect forward guidance." -- Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:IT

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. During the Q1 2026 e...

LKQ Shareholder Alert: LKQ Corporation Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP reminds purchasers of LKQ Corporation (NASDAQ: LKQ) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased LKQ securities between February 27, 2023 and July 23, 2025. YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. LKQ's...

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) shareholders lost approximately 6.4% of their investment value on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for Alzheimer's candidate diranersen (BIIB080) failed to meet its primary dose-response endpoint. Investors who lost money on BIIB are encouraged to submit their information for a free evaluation. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-75...
Back to Newsroom